Almac Group to Acquire BioClin Laboratories

Published on: 

Almac Group will acquire BioClin Laboratories to expand Almac’s analytical service offerings.

On Nov. 1, 2017, Almac Group, a contract development and manufacturing organization (CDMO), announced that it will acquire BioClin Laboratories, a contract analytical research and development company based in Athlone, Ireland that specializes in cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing, and good laboratory practice bioanalysis.

Under the terms of the acquisition, Almac will acquire BioClin’s 14,000-ft2 analytical facility to expand the CDMO’s analytical service offerings. This announcement follows a series of recent developments from Almac, including a multi-million pound expansion of Almac-owned chemical company Arran Chemical in October 2017, as well as new pharmaceutical development and manufacturing facilities located at the company’s Charnwood, Loughborough, England site, which passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in October 2017.

“We are delighted to announce this acquisition demonstrating further commitment to strategic growth and development of our global business,” said Dr. Stephen Barr, managing director, Almac Sciences, in a company press release. “Adding BioClin’s highly complementary analytical capacity and technical expertise to our existing capabilities, we are able to broaden our service offerings and address our global clients’ growing demands for a high quality, integrated, efficient service. We look forward to working with the BioClin team and plan to invest significantly in this facility.”


Source: Almac Group